{"data":[{"accessionNo":"0000053417-26-000064","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS INC","ticker":"PVLA","cusip":"697947109","securityClass":"Common Stock","eventDate":"2026-09-30","reportingPerson":"Jennison Associates LLC","reportingCik":null,"personType":"IA","sharesOwned":1101652,"percentOfClass":7.7,"filedAt":"2026-10-28","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0001999371-26-018011","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","cusip":"697947109","securityClass":"Common Stock, $0.01 par value","eventDate":"2026-06-30","reportingPerson":"Mathew P. Arens","reportingCik":null,"personType":"IN","sharesOwned":769117,"percentOfClass":5.34,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0001999371-26-018011","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","cusip":"697947109","securityClass":"Common Stock, $0.01 par value","eventDate":"2026-06-30","reportingPerson":"First Light Asset Management, LLC","reportingCik":null,"personType":"IA","sharesOwned":769117,"percentOfClass":5.34,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0000921895-26-002180","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","cusip":"697947109","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"BVF INC/IL","reportingCik":null,"personType":"CO","sharesOwned":672789,"percentOfClass":4.7,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0000921895-26-002180","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","cusip":"697947109","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"BVF PARTNERS L P/IL","reportingCik":null,"personType":"IA,PN","sharesOwned":672789,"percentOfClass":4.7,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0000921895-26-002180","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","cusip":"697947109","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"LAMPERT MARK N","reportingCik":null,"personType":"IN","sharesOwned":672789,"percentOfClass":4.7,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0000921895-26-002180","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","cusip":"697947109","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"BVF GP HOLDINGS LLC","reportingCik":null,"personType":"OO","sharesOwned":618359,"percentOfClass":4.3,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0000921895-26-002180","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","cusip":"697947109","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"BVF I GP LLC","reportingCik":null,"personType":"OO","sharesOwned":352699,"percentOfClass":2.5,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0000921895-26-002180","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","cusip":"697947109","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"BIOTECHNOLOGY VALUE FUND L P","reportingCik":null,"personType":"PN","sharesOwned":352699,"percentOfClass":2.5,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0000921895-26-002180","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","cusip":"697947109","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"BVF II GP LLC","reportingCik":null,"personType":"OO","sharesOwned":265660,"percentOfClass":1.9,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0000921895-26-002180","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","cusip":"697947109","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"BIOTECHNOLOGY VALUE FUND II LP","reportingCik":null,"personType":"PN","sharesOwned":265660,"percentOfClass":1.9,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0000921895-26-002180","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","cusip":"697947109","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"Biotechnology Value Trading Fund OS LP","reportingCik":null,"personType":"PN","sharesOwned":44510,"percentOfClass":0.3,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0000921895-26-002180","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","cusip":"697947109","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"BVF Partners OS Ltd.","reportingCik":null,"personType":"CO","sharesOwned":44510,"percentOfClass":0.3,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0001137774-26-000180","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","cusip":"697947109","securityClass":"Common","eventDate":"2026-06-30","reportingPerson":"PRUDENTIAL FINANCIAL INC","reportingCik":null,"personType":"HC","sharesOwned":962374,"percentOfClass":6.7,"filedAt":"2026-08-10","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0000053417-26-000050","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS INC","ticker":"PVLA","cusip":"697947109","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"Jennison Associates LLC","reportingCik":null,"personType":"IA","sharesOwned":960619,"percentOfClass":6.7,"filedAt":"2026-08-03","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0002012383-26-002924","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","cusip":"697947109","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"BlackRock, Inc.","reportingCik":null,"personType":"HC","sharesOwned":812953,"percentOfClass":5.7,"filedAt":"2026-07-29","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0001999371-26-003517","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","cusip":null,"securityClass":"Common Stock, $0.01 par value","eventDate":"2025-12-31","reportingPerson":"First Light Asset Management, LLC","reportingCik":null,"personType":"IA","sharesOwned":887031,"percentOfClass":7.49,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0001999371-26-003517","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","cusip":null,"securityClass":"Common Stock, $0.01 par value","eventDate":"2025-12-31","reportingPerson":"Mathew P. Arens","reportingCik":null,"personType":"IN","sharesOwned":887031,"percentOfClass":7.49,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0000921895-26-000471","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"BVF INC/IL","reportingCik":null,"personType":"CO","sharesOwned":879009,"percentOfClass":7.1,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0000921895-26-000471","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"BVF PARTNERS L P/IL","reportingCik":null,"personType":"IA,PN","sharesOwned":879009,"percentOfClass":7.1,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0000921895-26-000471","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"LAMPERT MARK N","reportingCik":null,"personType":"IN","sharesOwned":879009,"percentOfClass":7.1,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0000921895-26-000471","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"BVF GP HOLDINGS LLC","reportingCik":null,"personType":"OO","sharesOwned":813085,"percentOfClass":6.6,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0000921895-26-000471","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"BVF I GP LLC","reportingCik":null,"personType":"OO","sharesOwned":471202,"percentOfClass":3.8,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0000921895-26-000471","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"BIOTECHNOLOGY VALUE FUND L P","reportingCik":null,"personType":"PN","sharesOwned":471202,"percentOfClass":3.8,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0000921895-26-000471","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"BVF II GP LLC","reportingCik":null,"personType":"OO","sharesOwned":341883,"percentOfClass":2.8,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0000921895-26-000471","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"BIOTECHNOLOGY VALUE FUND II LP","reportingCik":null,"personType":"PN","sharesOwned":341883,"percentOfClass":2.8,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0000921895-26-000471","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"BVF Partners OS Ltd.","reportingCik":null,"personType":"CO","sharesOwned":53187,"percentOfClass":0.4,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0000921895-26-000471","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"Biotechnology Value Trading Fund OS LP","reportingCik":null,"personType":"PN","sharesOwned":53187,"percentOfClass":0.4,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0001231919-26-000151","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001583648","issuerName":"Palvella Therapeutics, Inc.","ticker":"PVLA","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"Frazier Life Sciences Public Fund, L.P.","reportingCik":null,"personType":"PN","sharesOwned":706360,"percentOfClass":6,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0001231919-26-000151","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001583648","issuerName":"Palvella Therapeutics, Inc.","ticker":"PVLA","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"FHMLSP, L.P.","reportingCik":null,"personType":"PN","sharesOwned":706360,"percentOfClass":6,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0001231919-26-000151","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001583648","issuerName":"Palvella Therapeutics, Inc.","ticker":"PVLA","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"FHMLSP, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":706360,"percentOfClass":6,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0001231919-26-000151","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001583648","issuerName":"Palvella Therapeutics, Inc.","ticker":"PVLA","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"Frazier Life Sciences XI, L.P.","reportingCik":null,"personType":"PN","sharesOwned":7517,"percentOfClass":0.1,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0001231919-26-000151","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001583648","issuerName":"Palvella Therapeutics, Inc.","ticker":"PVLA","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"FHMLS XI, L.P.","reportingCik":null,"personType":"PN","sharesOwned":7517,"percentOfClass":0.1,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0001231919-26-000151","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001583648","issuerName":"Palvella Therapeutics, Inc.","ticker":"PVLA","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"FHMLS XI, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":7517,"percentOfClass":0.1,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0001231919-26-000151","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001583648","issuerName":"Palvella Therapeutics, Inc.","ticker":"PVLA","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"Frazier Life Sciences X, L.P.","reportingCik":null,"personType":"PN","sharesOwned":4730,"percentOfClass":0,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0001231919-26-000151","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001583648","issuerName":"Palvella Therapeutics, Inc.","ticker":"PVLA","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"Patrick J. Heron","reportingCik":null,"personType":"IN","sharesOwned":4730,"percentOfClass":0,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0001231919-26-000151","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001583648","issuerName":"Palvella Therapeutics, Inc.","ticker":"PVLA","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"James N. Topper","reportingCik":null,"personType":"IN","sharesOwned":4730,"percentOfClass":0,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0001231919-26-000151","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001583648","issuerName":"Palvella Therapeutics, Inc.","ticker":"PVLA","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"Frazier Life Sciences XII, L.P.","reportingCik":null,"personType":"PN","sharesOwned":3793,"percentOfClass":0,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0001231919-26-000151","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001583648","issuerName":"Palvella Therapeutics, Inc.","ticker":"PVLA","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"FHMLS XII, L.P.","reportingCik":null,"personType":"PN","sharesOwned":3793,"percentOfClass":0,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0001231919-26-000151","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001583648","issuerName":"Palvella Therapeutics, Inc.","ticker":"PVLA","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"FHMLS XII, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":3793,"percentOfClass":0,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0001231919-26-000151","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001583648","issuerName":"Palvella Therapeutics, Inc.","ticker":"PVLA","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"FHMLS X, L.P.","reportingCik":null,"personType":"PN","sharesOwned":4730,"percentOfClass":0,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0001231919-26-000151","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001583648","issuerName":"Palvella Therapeutics, Inc.","ticker":"PVLA","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"FHMLS X, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":4730,"percentOfClass":0,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0000921895-25-003114","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"BVF PARTNERS L P/IL","reportingCik":null,"personType":"IA,PN","sharesOwned":1181194,"percentOfClass":9.99,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0000921895-25-003114","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"LAMPERT MARK N","reportingCik":null,"personType":"IN","sharesOwned":1181194,"percentOfClass":9.99,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0000921895-25-003114","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"BVF INC/IL","reportingCik":null,"personType":"CO","sharesOwned":1181194,"percentOfClass":9.99,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0000921895-25-003114","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"BVF GP HOLDINGS LLC","reportingCik":null,"personType":"OO","sharesOwned":1109047,"percentOfClass":9.4,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0000921895-25-003114","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"BIOTECHNOLOGY VALUE FUND L P","reportingCik":null,"personType":"PN","sharesOwned":634307,"percentOfClass":5.4,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0000921895-25-003114","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"BVF I GP LLC","reportingCik":null,"personType":"OO","sharesOwned":634307,"percentOfClass":5.4,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0000921895-25-003114","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"BIOTECHNOLOGY VALUE FUND II LP","reportingCik":null,"personType":"PN","sharesOwned":474740,"percentOfClass":4,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0000921895-25-003114","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"BVF II GP LLC","reportingCik":null,"personType":"OO","sharesOwned":474740,"percentOfClass":4,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0000921895-25-003114","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"BVF Partners OS Ltd.","reportingCik":null,"personType":"CO","sharesOwned":54840,"percentOfClass":0.5,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0000921895-25-003114","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001583648","issuerName":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"Biotechnology Value Trading Fund OS LP","reportingCik":null,"personType":"PN","sharesOwned":54840,"percentOfClass":0.5,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0000919574-25-006758","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001583648","issuerName":"Palvella Therapeutics, Inc.","ticker":"PVLA","cusip":null,"securityClass":"Common stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"AARON COWEN","reportingCik":null,"personType":"HC,IN","sharesOwned":822400,"percentOfClass":7.4,"filedAt":"2025-11-13","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0000919574-25-006758","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001583648","issuerName":"Palvella Therapeutics, Inc.","ticker":"PVLA","cusip":null,"securityClass":"Common stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"SUVRETTA CAPITAL MANAGEMENT, LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":822400,"percentOfClass":7.4,"filedAt":"2025-11-13","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"},{"accessionNo":"0000919574-25-006758","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001583648","issuerName":"Palvella Therapeutics, Inc.","ticker":"PVLA","cusip":null,"securityClass":"Common stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"AVERILL MASTER FUND, LTD.","reportingCik":null,"personType":"CO","sharesOwned":714463,"percentOfClass":6.5,"filedAt":"2025-11-13","canonicalUrl":"https://xoomar.com/markets/stocks/pvla"}],"updatedAt":"2026-11-03T19:37:56.847Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/pvla","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}